You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Relapsed/Refractory Mantle Cell Lymphoma: Where Do Novel BTK Inhibitors Fit for Our Patients?

  • Authors: Nirav N. Shah, MD; Pier Luigi Zinzani, MD, PhD
  • CME Released: 3/30/2023
  • Valid for credit through: 3/30/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, pathologists, and oncology care teams.

The goal of this activity is for learners to be better able to assess the latest data related to the use of BTK inhibitor therapy in patients with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and MCL, and integrate their use and management into current and future clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data on BTK inhibitors for patients with R/R MCL
    • Adverse events associated with BTK inhibitors for R/R MCL
  • Have greater competence related to
    • Selecting the appropriate BTK inhibitor for individual patients with R/R MCL
    • Managing treatment-related adverse events associated with BTK inhibitors for R/R MCL


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

-


Faculty

  • Nirav N. Shah, MD

    Associate Professor
    Medical College of Wisconsin
    Brookfield, Wisconsin, United States

    Disclosures

    Nirav N. Shah, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb Company; Epizyme Inc.; Incyte Corporation; Kite Pharma, Inc.; Lilly Oncology; Miltenyi Biotec; Novartis; TG Therapeutics, Inc.
    Research funding from: Lilly Oncology; Miltenyi Biotec

  • Pier Luigi Zinzani, MD, PhD

    Professor
    Head of Lymphoma Group
    Lymphoma and Chronic Lymphoproliferative Syndromes Unit
    Institute of Hematology "L. e A. Serà gnoli"
    University of Bologna
    Bologna, Italy

    Disclosures

    Pier Luigi Zinzani, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; AstraZeneca; Bayer; BeiGene (Beijing) Co., Ltd; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; Incyte Corporation; Kyowa Kirin Pharmaceutical Development, Inc.; Janssen; Merck Sharp & Dohme GmbH; Novartis; Roche; Takeda
    Speaker or member of speakers bureau for: AbbVie, Inc.; AstraZeneca; Bayer; BeiGene (Beijing) Co., Ltd; Bristol Myers Squibb Company; Eli Lilly and Company; Gilead Sciences, Inc.; Incyte Corporation; Kyowa Kirin Pharmaceutical Development, Inc.; Janssen; Merck Sharp & Dohme GmbH; Novartis; Roche; Takeda

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek has no relevant financial relationships.

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a collaboration between The Leukemia & Lymphoma Society and Medscape Oncology.

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Relapsed/Refractory Mantle Cell Lymphoma: Where Do Novel BTK Inhibitors Fit for Our Patients?

Authors: Nirav N. Shah, MD; Pier Luigi Zinzani, MD, PhDFaculty and Disclosures

CME Released: 3/30/2023

Valid for credit through: 3/30/2024, 11:59 PM EST

processing....

  • Print